AUS
NZ
UK
CA
USA
IND
Healt
Healius Boosts Shareholder Returns with $300 Million Special Dividend: A Positive Signal in ASX200
May 05, 2025 02:30 PM AEST| By Team Kalkine MediaHighlights,Healius announces fully franked special dividend.,Distribution totals approximately $300 million.,Share price rises over 4% following announcement.,Healthcare and diagnostic services provider,Healius,(ASX:HLS) has announced a significant m...
Cadoux (ASX:CDX) Powers Ahead in HPA and Rare Earths with Strategic Moves and ASX200 Growth Potential
May 05, 2025 12:53 PM AEST| By Team Kalkine MediaHighlights,FEED studies initiated for high purity alumina plant,Minhub feasibility study completed in Darwin,Focus on EV, battery, and rare earth market demand,Cadoux Ltd (ASX:CDX),made notable strides during the March 2025 quarter, progressing its H...
Alterity Therapeutics (ASX:ATH) Gains FDA Fast-Track Status Amid ASX 200 Biotech Developments
May 05, 2025 11:30 AM AEST| By Team Kalkine MediaHighlights:,Alterity Therapeutics (ASX:ATH) received FDA fast-track designation for its neurological therapy ATH434,Trading volume surged on the ASX and NASDAQ amid high share activity,Biotech sector, including Alterity, aligns with broader developme...
Biotech Breakthrough and ASX 200 Movement: ATH, GOR, HZR Drive Industry Updates
May 05, 2025 11:30 AM AEST| By Team Kalkine MediaHighlights,Alterity Therapeutics (ASX:ATH) receives Fast Track designation from the U.S. FDA for a rare neurological disorder treatment,Gold Road Resources (ASX:GOR) enters strategic agreement with Gold Fields to advance sector consolidation,Hazer Gr...
Why Cochlear (ASX:COH) May Be a Standout in ASX200 Healthcare Stocks in 2025
May 05, 2025 10:41 AM AEST| By Team Kalkine MediaHighlights,COH shares trade below historical valuation,Healthcare sector shows stable, long-term potential,Growing appeal for ethical and sustainable investing,Cochlear (ASX:COH), the global leader in hearing implant technology, has seen its share pr...
Key Insider Activity at Althea Group Holdings (ASX:AGH) – Insight on Recent Developments
May 03, 2025 02:34 PM AEST| By Team Kalkine MediaHighlights:,CEO Joshua Fegan made a significant stock purchase in Althea Group Holdings (ASX:AGH).,Over the last year, the company experienced a net buying trend in insider transactions.,Despite strong insider alignment, there are notable concerns re...
Sigma Healthcare's Post-Merger Momentum: What's Driving Investor Interest in this ASX200 Stock
May 02, 2025 04:01 PM AEST| By Team Kalkine MediaHighlights,Sigma Healthcare's growth outlook shines post-Chemist Warehouse merger,Valuation premium seen as justified by strong defensive earnings,11% upside potential highlighted by analysts,Sigma Healthcare (ASX:SIG) is gaining renewed attention fo...
Island Pharmaceuticals ASX:ILA Transactions: Ownership and Share Trends Reviewed | ASX All Ordinaries & ASX 200
May 02, 2025 02:35 PM AEST| By Team Kalkine MediaHighlights,Market capitalization increased significantly for Island Pharmaceuticals (ASX:ILA) during the year,Company insiders showed more buying activity than selling over the review period,Ownership by company insiders remains a substantial portion...
Ownership Breakdown of Healius Limited (ASX:HLS) and Its Market Dynamics
May 02, 2025 02:32 PM AEST| By Team Kalkine MediaHighlights,:,Institutional investors own a major portion of Healius.,Private equity firms possess a significant stake in the company.,Insiders and the general public hold relatively smaller shares,Healius Limited (ASX:HLS) is a key player in the heal...
Is Biotech Volatility Reshaping Imugene's Path in the ASX All Ordinaries Index?
May 02, 2025 01:30 PM AEST| By Team Kalkine MediaIs Biotech Volatility Reshaping Imugene's Path in the ASX All Ordinaries Index?
CSL (ASX:CSL): Is This Healthcare Giant Still a Staple in ASX200?
May 02, 2025 12:55 PM AEST| By Team Kalkine MediaHighlights,CSL revenue grows at 12.8% CAGR over three years,Profit reaches $2.64 billion in FY24,Debt/equity ratio,remains,balanced at 62.8%,Shares of biotechnology heavyweight,CSL (ASX:CSL),have seen a decline of 10.69% since the start of 2025, spar...
Nyrada (ASX:NYR) Advances Clinical Trials with NYR-BI03 Amid ASX 200 Biopharma Developments
May 02, 2025 12:30 PM AEST| By Team Kalkine MediaHighlights:,Nyrada (ASX:NYR) progresses to a new phase in its clinical evaluation of NYR-BI03,NYR-BI03 demonstrates effectiveness in neuroprotection and cardiac research models,Collaborative studies expand the therapeutic profile of NYR-BI03 in brain...
Race Oncology Reaches Critical Trial Milestone with RC220 Cancer Drug
May 02, 2025 11:10 AM AEST| By Team Kalkine MediaHighlights,First patient dosed in Phase 1 RC220 trial,Breakthrough formulation,eliminates,prior safety concern,Global trial expansion planned in 2025,Race Oncology (ASX:RAC) has marked a significant milestone with the successful dosing of the first p...
Healius (ASX:HLS) Surges on ASX 200 After $822 Million Imaging Unit Sale
May 01, 2025 06:29 PM AEST| By Team Kalkine MediaHighlights,Healius rallies post Lumus Imaging divestment,$822 million cash proceeds boost company momentum,Special dividend announced as part of reshaping strategy,Healius (ASX:HLS), a prominent player in Australia's healthcare sector, saw its shares...
ASX Health Sector Update: ILA, TYP, DXB, OIL Drive Innovations on All Ordinaries
May 01, 2025 04:33 PM AEST| By Team Kalkine MediaHighlights:,Island Pharmaceuticals completed Phase 2a/b dengue trial and advanced Galidesivir acquisition,Tryptamine Therapeutics progressed psilocin-based TRP-8803 in binge eating disorder trial,Dimerix secured DMX-200 licensing deals and advanced P...
Imugene Ramps Up Clinical Momentum Amid Strong Trial Results and ASX 200 Positioning
May 01, 2025 03:55 PM AEST| By Team Kalkine MediaHighlights,Imugene reports strong trial outcomes for azer-cel in DLBCL,Fast Track Designation granted by US FDA for azer-cel therapy,Expanded patents and improved cash reserves boost growth potential,Imugene Ltd (ASX:IMU) advanced significantly in th...
Dimerix Secures Major US Partnership for Kidney Drug Amid Growing ASX 200 Healthcare Momentum
May 01, 2025 02:29 PM AEST| By Team Kalkine MediaHighlights,Dimerix inks US licensing deal with Amicus for kidney drug DMX-200,Agreement includes up to US$560 million in milestone payments,Addresses urgent need for treatment in rare kidney disease FSGS,Australian biotech company Dimerix (ASX:DXB) h...
EVE Health Makes Bold Therapeutics Pivot with Nextract Deal, Tapping Into Multi-Billion-Dollar Markets | ASX 200 Watch
May 01, 2025 02:16 PM AEST| By Team Kalkine MediaHighlights,EVE Health pivots into global therapeutics with Nextract acquisition,Targets erectile dysfunction and period pain markets,Launch plans underway with expansion into MENA region,EVE Health (ASX:EVE) is embarking on a transformative journey,...
ASX 200 Short Interest Review: BHP, Sigma Pharmaceuticals, and Alcoa Movement Overview
April 30, 2025 10:15 PM AEST| By Team Kalkine MediaHighlights:,Short interest trends observed across,BHP Group,(ASX:BHP), Sigma Pharmaceuticals (ASX:SIP), and Alcoa Corporation (ASX:AAI),Shifts recorded in overall short positioning across selected stocks in the materials and healthcare sectors,Weekly...
Is Sonic Healthcare (ASX:SHL) Undervalued in 2025? A Closer Look at the Metrics
April 30, 2025 05:10 PM AEST| By Team Kalkine MediaHighlights,Sonic Healthcare shares trade below historical valuation levels,Revenue shows marginal growth, while profit has declined,Debt levels are notable but equity position remains stronger,The share price of Sonic Healthcare (ASX:SHL), one of the...
Advertise your brand on Kalkine Media